Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 15/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | UBE2M | P61081 | 1/20 | 0.40 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727486 | 0.96 | HDAC3 (0.41) | SIGMAR1RXFP1UBE2MDCUN1D1HDAC3 | |
| SCHEMBL8181403 | 0.86 | SIGMAR1 (0.55) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL8501635 | 0.85 | SIGMAR1 (0.56) | SIGMAR1 | |
| SCHEMBL6158214 | 0.84 | SIGMAR1 (0.51) | SIGMAR1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6728064 | 0.83 | SIGMAR1 (0.55) | SIGMAR1 | |
| SCHEMBL6724099 | 0.83 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL6719563 | 0.83 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL6724566 | 0.83 | MEN1 (0.49) | SIGMAR1RXFP1 | |
| SCHEMBL6717419 | 0.82 | HDAC3 (0.46) | SIGMAR1RXFP1UBE2MDCUN1D1HDAC3 | |
| SCHEMBL6721291 | 0.81 | SIGMAR1 (0.52) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673557-B2 | ADMINISTERING SUBSTITUED GUANIDINE COMPOUNDS FOR THERAPY OF DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2004-01-06 | — | — | US | claimed |
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | WYETH | 2003-02-06 | — | — | US | claimed |
| US-6358696-B1 | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF ONE OR MORE SUBSTITUTED GUANIDINES TO TREAT DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2002-03-19 | — | — | US | claimed |
| US-6242198-B1 | ADMINISTERING GUANIDINE COMPOUND | CAMBRIDGE NEUROSCIENCE, INC. | 2001-06-05 | — | — | US | claimed |
| US-6013675-A | ADMINISTERING TO THE MAMMAL A SUBSTITUTED GUANIDINE COMPOUNDS FOR TREATING THE DISEASE OF NERVOUS SYSTEM IN WHICH PATHOPHYSIOLOGY OF THE DISORDER INVOLVES EXCESSIVE ACTIVATION OF NERVE CELLS BY AGONIST OF METHYL ASPARTATE RECEPTORS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-01-11 | — | — | US | claimed |
| US-5922772-A | PREVENTS OVERACTIVATION OF NMDA TYPE RECEPTORS BY GLUTAMATE; BINDS TO PCP TYPE RECEPTOR, ACTING AS A NONCOMPETITIVE ANTAGONIST, TREATMENT OF ALZHEIMER'S, PARKINSON'S, HUNTINGTON'S DISEASES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-07-13 | — | — | US | claimed |
| EP-0918460-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-06-02 | — | — | EP | claimed |
| WO-1998004131-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-02-05 | — | — | WO | claimed |
| EP-0739200-A4 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE INC (US) | 1997-12-17 | — | — | EP | claimed |
| EP-0739200-A1 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1996-10-30 | — | — | EP | claimed |
| WO-1995014461-A1 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-06-01 | — | — | WO | claimed |
| US-6673557-B2 | ADMINISTERING SUBSTITUED GUANIDINE COMPOUNDS FOR THERAPY OF DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2004-01-06 | — | — | US | disclosed |
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | WYETH | 2003-02-06 | — | — | US | disclosed |
| US-6358696-B1 | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF ONE OR MORE SUBSTITUTED GUANIDINES TO TREAT DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2002-03-19 | — | — | US | disclosed |
| US-6242198-B1 | ADMINISTERING GUANIDINE COMPOUND | CAMBRIDGE NEUROSCIENCE, INC. | 2001-06-05 | — | — | US | disclosed |
| WO-1999002145-A1 | COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
| WO-1998004131-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0739200-A4 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE INC (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0739200-A1 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995014461-A1 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | RBP4, ALDH1A2, RBP1 | SIGMAR1 3775/4885RXFP1 429/4885UBE2M 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.